CoreValve

    CoreValve was acquired by Medtronic in 2009 for $700 million, plus milestone payments. CoreValve developed a Percutaneous Aortic Valve to replace open heart surgery with a minimally invasive approach. The product was approved in Europe and many other countries, with more than 25,000 patients treated to date. CoreValve is considered as one of the most successful private medtech exits in the last 10 years. The company was founded by Prof Jacques Seguin, a cardiac surgeon and repeat entrepreneur in the cardiovascular space.

    SofinnovaCapital

    The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

    SofinnovaMD Start

    The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.

    SofinnovaCrossover

    The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

    SofinnovaIndustrial Biotech

    Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.

    SofinnovaTelethon

    The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

    Welcome to our new website – a fresh look that represents a new SofinnovaFind out more